Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-201 and pembrolizumab in advanced solid tumors
NCT03476681Phase 2Active, not recruiting
- Sponsor
- Precision Biologics
- Start
- Jan 2019
- Primary completion
- Jun 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NEO-201 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Cervical Cancer (CC) and 1 more, sponsored by Precision Biologics. Primary endpoints: Safety of NEO-201 with pembrolizumab (CTCAE v5.0) at 1.5 years, Objective Response Rate at 1.5 years and 1 more. Started Jan 2019; status: active, not recruiting.
02
Drugs
NEO-201
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Cervical Cancer (CC)uterine cancer
Beyond the preview
Go deeper on NCT03476681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03476681.